Managing argatroban in heparin‐induced thrombocytopenia: A retrospective analysis of 729 treatment days in 32 patients with confirmed heparin‐induced thrombocytopenia.

Managing argatroban in heparin-induced thrombocytopenia: A retrospective analysis of 729 treatment days in 32 patients with confirmed heparin-induced thrombocytopenia Keywords: anticoagulation; argatroban; argatroban monitoring; heparin-induced thrombocytopenia; plasmatic argatroban concentration EN anticoagulation argatroban argatroban monitoring heparin-induced thrombocytopenia plasmatic argatroban concentration 766 790 25 06/14/22 20220615 NES 220615 Summary Argatroban is a first-line anticoagulant for patients with heparin-induced thrombocytopenia (HIT). Monitoring argatroban with thrombin-time-based assays is in line with current expert's opinions.21 Argatroban half-life after discontinuation We found an argatroban plasma half-life of about 1 h in patients with normal liver function (Figure 2A,B). Patients with liver cytolysis tended to require lower median argatroban doses at steady state than patients with normal liver function, in order to reach prophylactic and high therapeutic PAC intervals. [Extracted from the article]